Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

TBK1 inhibition unleashes RIPK1, resensitizing tumors to immunotherapy

Trends in Immunology(2023)10.1016/j.it.2023.01.009Source: DataRank Database

TBK1 inhibition unleashes RIPK1, resensitizing tumors to immunotherapy is a research paper published in Trends in Immunology (2023). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

6 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.87)OA: closedTopics (28)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Katherine A. Fitzgerald ORCID,Michelle A. Kelliher ORCID

Live enrichment

PubMed:36740513 OpenAlex:https://openalex.org/W4319233447

National Institutes of Health

Grant: AI067497

National Institutes of Health

Grant: AI075118

NIAID NIH HHS

Grant: R01 AI075118

NIAID NIH HHS

Grant: R01 AI067497

FWCI

0.87

Citation Percentile

0.7%

Citation Trend

2023

2024

2025

2026

closedLicense: https://doi.org/10.15223/policy-004

publisherhttps://api.elsevier.com/content/article/PII:S1471490623000236?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1471490623000236?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.it.2023.01.009

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36740513

Fields of Study

interferon and immune responsesCancer Immunotherapy and BiomarkersPhagocytosis and Immune Regulation

MeSH Terms

HumansImmunotherapyNeoplasmsCell DeathProtein Serine-Threonine KinasesReceptor-Interacting Protein Serine-Threonine Kinases

Keywords

TANK-binding kinase 1BlockadeCancer researchImmunotherapyRIPK1KinaseImmunologyImmune checkpointMedicineBiologyImmune systemProgrammed cell deathInternal medicineNecroptosisProtein kinase AReceptorMAP kinase kinase kinaseCell biologyGenetics

Sustainable Development Goals

SDG 0: Good health and well-being

TBK1 inhibition unleashes RIPK1, resensitizing tumors to immunotherapy

FAIR Checklist

Authors (2)

Funding (4 grants)

Impact

Open Access

Topics